Loading clinical trials...
Loading clinical trials...
A Single Arm, Open Label, Phase 1b Study of Xevinapant in Combination With Weekly Cisplatin and Intensity-modulated Radiotherapy to Assess Safety and Tolerability in Participants With LA SCCHN, Suitable for Definitive Chemoradiotherapy (HyperlynX)
Conditions
Interventions
Xevinapant
Cisplatin
+1 more
Locations
23
United States
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States
Karmanos Cancer Institute - PARENT
Detroit, Michigan, United States
Montefiore Medical Center PRIME
The Bronx, New York, United States
Cleveland Clinic
Cleveland, Ohio, United States
Avera McKennan Hospital and University Health Center
Sioux Falls, South Dakota, United States
Uza - Parent
Edegem, Belgium
Start Date
January 18, 2024
Primary Completion Date
August 20, 2024
Completion Date
August 20, 2024
Last Updated
September 29, 2025
NCT04585750
NCT06636188
NCT07457346
NCT05526924
NCT07065630
NCT07447050
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions